---
title: CDMO Daily News — July 29, 2026
slug: daily-news-2026-07-29-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: July 29 CDMO daily: AsymBio Expands Shanghai Biologics R&D with New Eight-Story Facility; AsymBio Breaks Ground on Shanghai Fengxian R&D Building for…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-07-29-cdmo
published_at: 2026-07-29T00:00:53.236Z
last_updated: 2026-07-29T00:01:58.185Z
---

### [AsymBio](/companies/asymbio) Expands Shanghai Biologics R&D with New Eight-Story Facility
- [AsymBio](/companies/asymbio) broke ground in May 2026 on an eight-story R&D building at its Shanghai Fengxian site, with completion targeted for H2 2027.
- The ~20,000 sq m facility will support cell line development, process development for antibodies and ADCs, and house AsymBio's AI-enabled AccPCC platform.
- Co-location with existing clinical and commercial manufacturing lines is designed to streamline development-to-manufacturing scale-up and shorten project timelines.

**Operational Impact**

[AsymBio](/companies/asymbio)'s new Shanghai R&D facility strengthens its APAC biologics development footprint and co-located manufacturing capacity, enabling faster development-to-manufacturing transitions for antibody and ADC partners through integrated CMC decision-making.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/asymbio-breaks-ground-on-new-shanghai-biologics-rd-building)*

---

### [AsymBio](/companies/asymbio) Breaks Ground on Shanghai Fengxian R&D Building for Biologics Development
- AsymBio is constructing an eight-story, 20,000-square-meter R&D facility at its Shanghai Fengxian site, with completion targeted for H2 2027.
- The building will support cell line development, upstream/downstream process development, ADC conjugation, drug product development, and analytical services adjacent to clinical and commercial manufacturing lines.
- The facility will house AccPCC, an AI-enabled platform designed to integrate early R&D, CMC, and nonclinical evaluation to accelerate development timelines from lead to preclinical candidate selection.

**Operational Impact**

[AsymBio](/companies/asymbio)'s Fengxian R&D facility adds integrated development-to-manufacturing capacity for antibodies and ADCs in APAC, enabling tighter CMC alignment and shorter timelines for clients scaling programs from preclinical through commercial manufacturing.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/asymbio-breaks-ground-on-new-fengxian-rd-building)*

---

### [Asymchem](/companies/asymchem)'s Jilin Carbapenem API Facility Passes First FDA Pre-Approval Inspection
- [Asymchem](/companies/asymchem)'s DH2 carbapenem API facility in Jilin, China completed its first USFDA Pre-Approval Inspection in June 2026, supporting commercial manufacturing using continuous flow technology.
- The facility, commissioned in 2020, features in-house designed continuous ozonolysis capabilities at tonnage scale and serves clinical through commercial supply chains for carbapenems.

**Operational Impact**

[Asymchem](/companies/asymchem)'s Jilin DH2 facility PAI clearance expands validated carbapenem API capacity for CDMO customers, particularly those seeking continuous flow-manufactured intermediates for commercial supply.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/asymchems-carbapenem-api-facility-passes-first-usfda-pre-approval-inspection)*

## References

1. [PharmaSource RSS — AsymBio Expands Shanghai Biologics R&D with New Eight-Story Facility](https://pharmasource.global/content/news/cdmo-news/asymbio-breaks-ground-on-new-shanghai-biologics-rd-building)
2. [Contract Pharma Breaking News RSS — AsymBio Breaks Ground on Shanghai Fengxian R&D Building for Biologics Development](https://www.contractpharma.com/breaking-news/asymbio-breaks-ground-on-new-fengxian-rd-building)
3. [PharmaSource RSS — Asymchem's Jilin Carbapenem API Facility Passes First FDA Pre-Approval Inspection](https://pharmasource.global/content/news/cdmo-news/asymchems-carbapenem-api-facility-passes-first-usfda-pre-approval-inspection)

Source: https://www.cdmo.directory/posts/daily-news-2026-07-29-cdmo